• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Veru Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    3/13/26 4:04:22 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERU alert in real time by email
    veru20260312_8k.htm
    false 0000863894 0000863894 2026-03-12 2026-03-12


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): March 12, 2026
     

     
    VERU INC.
    (Exact name of registrant as specified in its charter)
     
    Wisconsin
    1-13602
    39-1144397
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
     
    2916 North Miami Avenue, Suite 1000, Miami, Florida 33127
    (Address of principal executive offices) (Zip Code)
     
    Registrant’s telephone number, including area code: (305) 509-6897
     
    Not Applicable
    (Former name or former address, if changed since last report.)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐ 
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐ 
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐ 
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐ 
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.01 par value per share
    VERU
    NASDAQ Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     

     
     
    Section 5 – Corporate Governance and Management
     
    Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
     
    At the 2026 Annual Meeting of Shareholders (the "Annual Meeting") of Veru Inc. (the "Company") held on March 12, 2026, the Company’s shareholders approved a proposal to amend the Veru Inc. 2018 Equity Incentive Plan (the "Equity Incentive Plan") to (1) increase the number of shares of the Company’s Common Stock authorized for issuance under the Equity Incentive Plan from 2,600,000 shares to 5,850,000 shares, (2) increase the annual limit on awards to participants other than non-employee directors from 100,000 shares to 750,000 shares, and (3) increase the annual limit on awards to non-employee directors from 10,000 shares to 120,000 shares. A copy of the Equity Incentive Plan, as amended, is attached hereto as Exhibit 10.1.
     
    A summary description of the terms of the Equity Incentive Plan is set forth in the Company's definitive proxy statement (the "Proxy Statement") on Schedule 14A filed with the Securities and Exchange Commission on January 28, 2026. The section of the Proxy Statement entitled "Proposal 3: Approval of the Amendment to the 2018 Equity Incentive Plan" from pages 26 to 33 is incorporated herein by reference.
     
    Item 5.07.         Submission of Matters to a Vote of Security Holders.
     
    The Company held the Annual Meeting on March 12, 2026. A total of 16,050,320 shares of the Company’s common stock were eligible to vote at the Annual Meeting. The matters voted on at the Annual Meeting were as follows:
     
    1.
    Election of Directors:
     
    The following individuals were nominated for election to the Board of Directors for terms that expire at the next annual meeting of shareholders. All of the nominated directors were elected. The results of the vote on the election of directors were as follows:
     
    Name
     
    Votes
    For
       
    Votes
    Withheld
       
    Broker
    Non-Votes
     
    Mitchell S. Steiner
        5,381,201       394,511       4,423,999  
    Harry Fisch
        5,483,627       292,085       4,423,999  
    Michael L. Rankowitz
        5,331,961       443,751       4,423,999  
    Grace Hyun
        5,384,328       391,384       4,423,999  
    Lucy Lu
        5,435,927       339,785       4,423,999  
    Loren Katzovitz
        5,498,489       277,223       4,423,999  
     
    2.
    Ratification of Auditors:
     
    The shareholders voted to ratify the appointment by the Company's Audit Committee of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2026.
     
    Votes For
       
    Votes Against
       
    Abstentions
       
    Broker Non-Votes
     
    10,040,215       115,840       43,656       0  
     
    3.
    Amendment of the Equity Incentive Plan:
     
    The shareholders voted in favor of amending the Equity Incentive Plan.
     
    Votes For
       
    Votes Against
       
    Abstentions
       
    Broker Non-Votes
     
    4,743,572       975,452       56,688       4,423,999  
     
    2

     
     
    4.
    Advisory (non-binding) vote on the executive compensation of the Company's named executive officers:
     
    The shareholders voted in favor of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting.
     
    Votes For
       
    Votes Against
       
    Abstentions
       
    Broker Non-Votes
     
    4,476,916       735,523       563,273       4,423,999  
     
    5.
    Adjournment Proposal:
     
    The shareholders voted in favor of approving the adjournment of the Special Meeting if necessary or appropriate in the view of the Company’s Board of Directors, including to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals.
     
    Votes For
       
    Votes Against
       
    Abstentions
       
    Broker Non-Votes
     
    9,045,655       1,106,328       47,728       0  
     
    3
     
     
    Section 9 – Financial Statements and Exhibits
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d) Exhibits.
     
    Exhibit No.
     
    Description
    10.1
     
    Veru Inc. 2018 Equity Incentive Plan (as amended and restated effective March 12, 2026).
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
    4
     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Date: March 13, 2026
    VERU INC.
         
     
    By: 
    /s/ Michele Greco                                             
       
    Michele Greco
       
    Chief Financial Officer and
        Chief Administrative Officer
     
    5
    Get the next $VERU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERU

    DatePrice TargetRatingAnalyst
    12/18/2025$25.00Buy
    Canaccord Genuity
    5/14/2024$5.00Buy
    B. Riley Securities
    3/28/2024$3.00Outperform
    Raymond James
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Barnette K Gary

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:29:58 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rankowitz Michael L

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:19:11 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Katzovitz Loren Mark

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:10:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

    -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide -- -- Interim analysis expected in the first quarter calendar year 2027---- Final topline clinical data expected in the fourth quarter calendar year 2027-- MIAMI, FL, March 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that it has enrolled the first patient in its Phase 2b PLATEAU

    3/9/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 pm – 3:50 pm ET. A live webcast will be accessible through the Company's website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru website. About Veru Inc.Veru is a late clinical stage biopharm

    2/19/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    SEC Filings

    View All

    Veru Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - VERU INC. (0000863894) (Filer)

    3/13/26 4:04:22 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Veru Inc.

    10-Q - VERU INC. (0000863894) (Filer)

    2/11/26 10:32:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - VERU INC. (0000863894) (Filer)

    2/11/26 7:00:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Veru with a new price target

    B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00

    5/14/24 8:03:44 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Veru with a new price target

    Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00

    3/28/24 7:50:24 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    2/20/25 10:00:11 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/28/24 5:04:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/24/24 6:57:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Leadership Updates

    Live Leadership Updates

    View All

    Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

    MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

    6/1/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

    MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi

    1/10/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

    MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan

    8/19/22 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Financials

    Live finance-specific insights

    View All

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal Year 2025 Financial Results on December 17th

    MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.

    12/10/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/12/24 9:34:37 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/4/24 4:19:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Veru Inc.

    SC 13G - VERU INC. (0000863894) (Subject)

    4/24/24 4:16:01 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care